Last reviewed · How we verify
SCT630
SCT630 is a stem cell therapy that aims to regenerate or replace damaged tissue through cellular transplantation.
At a glance
| Generic name | SCT630 |
|---|---|
| Sponsor | Sinocelltech Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a cell therapy product from Sinocelltech, SCT630 likely involves the use of stem cells or progenitor cells to promote tissue repair and regeneration. The exact mechanism depends on the cell type and target tissue, but generally works by replacing damaged cells, secreting therapeutic factors, or modulating the immune environment to promote healing.
Approved indications
Common side effects
Key clinical trials
- The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis (PHASE3)
- Pharmacokinetics and Safety in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCT630 CI brief — competitive landscape report
- SCT630 updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI